Literature DB >> 29574692

P2Y12 receptor modulation of ADP-evoked intracellular Ca2+ signalling in THP-1 human monocytic cells.

J J Micklewright1, J A Layhadi1, S J Fountain1.   

Abstract

BACKGROUND AND
PURPOSE: The Gi -coupled, ADP-activated P2Y12 receptor is well characterized as playing a key role in platelet activation via crosstalk with the P2Y1 receptor in ADP-evoked intracellular Ca2+ responses. However, there is limited knowledge on the role of P2Y12 receptors in ADP-evoked Ca2+ responses in other blood cells. Here, we investigated the role of P2Y12 receptor activation in the modulation of ADP-evoked Ca2+ responses in human THP-1 monocytic cells. EXPERIMENTAL APPROACH: A combination of intracellular Ca2+ measurements, RT-PCR, immunocytochemistry, leukocyte isolation and siRNA-mediated gene knockdown were used to identify the role of P2Y12 receptor activation. KEY
RESULTS: ADP-evoked intracellular Ca2+ responses (EC50 2.7 μM) in THP-1 cells were abolished by inhibition of PLC (U73122) or sarco/endoplasmic reticulum Ca2+ -ATPase (thapsigargin). Loss of ADP-evoked Ca2+ responses following treatment with MRS2578 (IC50 200 nM) revealed a major role for P2Y6 receptors in mediating ADP-evoked Ca2+ responses. ADP-evoked responses were attenuated either with pertussis toxin treatment, or P2Y12 receptor inhibition with two chemically distinct antagonists (ticagrelor, IC50 5.3 μM; PSB-0739, IC50 5.6 μM). ADP-evoked responses were suppressed following siRNA-mediated P2Y12 gene knockdown. The inhibitory effects of P2Y12 antagonists were fully reversed following adenylate cyclase inhibition (SQ22536). P2Y12 receptor expression was confirmed in freshly isolated human CD14+ monocytes. CONCLUSIONS AND IMPLICATIONS: Taken together, these data suggest that P2Y12 receptor activation positively regulates P2Y6 receptor-mediated intracellular Ca2+ signalling through suppression of adenylate cyclase activity in human monocytic cells.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29574692      PMCID: PMC5980558          DOI: 10.1111/bph.14218

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase.

Authors:  D Communi; C Govaerts; M Parmentier; J M Boeynaems
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

2.  Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6 receptors. SER-333 and SER-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y4 receptor.

Authors:  A E Brinson; T K Harden
Journal:  J Biol Chem       Date:  2000-12-12       Impact factor: 5.157

3.  Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling.

Authors:  Xiaoyu Zhang; Juliang Qin; Junyan Zou; Zhangsheng Lv; Binghe Tan; Jueping Shi; Yihan Zhao; Hua Ren; Mingyao Liu; Min Qian; Bing Du
Journal:  Cell Mol Immunol       Date:  2016-11-21       Impact factor: 11.530

Review 4.  The CD14+ CD16+ blood monocytes: their role in infection and inflammation.

Authors:  Loems Ziegler-Heitbrock
Journal:  J Leukoc Biol       Date:  2006-11-29       Impact factor: 4.962

5.  Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP.

Authors:  Abduelhakem Ben Addi; Dorothée Cammarata; Pamela B Conley; Jean-Marie Boeynaems; Bernard Robaye
Journal:  J Immunol       Date:  2010-10-15       Impact factor: 5.422

6.  Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.

Authors:  Adam R Hardy; Matthew L Jones; Stuart J Mundell; Alastair W Poole
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

7.  Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.

Authors:  J Jin; S P Kunapuli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

Authors:  Steen Husted; Håkan Emanuelsson; Stan Heptinstall; Per Morten Sandset; Mark Wickens; Gary Peters
Journal:  Eur Heart J       Date:  2006-02-13       Impact factor: 29.983

9.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.

Authors:  Riyaad Aungraheeta; Alexandra Conibear; Mark Butler; Eamonn Kelly; Sven Nylander; Andrew Mumford; Stuart J Mundell
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

View more
  12 in total

1.  ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation.

Authors:  Harika Vemulapalli; Samara Albayati; Viren C Patwa; Douglas G Tilley; Alexander Y Tsygankov; Elisabetta Liverani
Journal:  J Cell Commun Signal       Date:  2019-12-05       Impact factor: 5.782

2.  Inhibitors of DAG metabolism suppress CCR2 signalling in human monocytes.

Authors:  Priscilla Day; Lisa Burrows; David Richards; Samuel J Fountain
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

3.  Nucleotides modulate synoviocyte proliferation and osteoclast differentiation in macrophages with potential implications for rheumatoid arthritis.

Authors:  Sai Krishna Srimadh Bhagavatham; Vishnu Kannan; V M Datta Darshan; Venketesh Sivaramakrishnan
Journal:  3 Biotech       Date:  2021-11-19       Impact factor: 2.406

4.  P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.

Authors:  Junzhe Chen; Ying Tang; Yu Zhong; Biao Wei; Xiao-Ru Huang; Patrick Ming-Kuen Tang; Anping Xu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2022-07-05       Impact factor: 12.910

5.  Pharmacological and genetic characterisation of the canine P2X4 receptor.

Authors:  Reece A Sophocleous; Tracey Berg; Rocio K Finol-Urdaneta; Vanessa Sluyter; Shikara Keshiya; Lachlan Bell; Stephen J Curtis; Belinda L Curtis; Aine Seavers; Rachael Bartlett; Mark Dowton; Leanne Stokes; Lezanne Ooi; Ronald Sluyter
Journal:  Br J Pharmacol       Date:  2020-03-10       Impact factor: 8.739

6.  ATP-Evoked Intracellular Ca2+ Responses in M-CSF Differentiated Human Monocyte-Derived Macrophage are Mediated by P2X4 and P2Y11 Receptor Activation.

Authors:  Janice A Layhadi; Samuel J Fountain
Journal:  Int J Mol Sci       Date:  2019-10-15       Impact factor: 5.923

7.  Activated Platelets Convert CD14+CD16- Into CD14+CD16+ Monocytes With Enhanced FcγR-Mediated Phagocytosis and Skewed M2 Polarization.

Authors:  Su Jeong Lee; Bo Ruem Yoon; Hee Young Kim; Su-Jin Yoo; Seong Wook Kang; Won-Woo Lee
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

Review 8.  P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.

Authors:  Alexandre Mansour; Christilla Bachelot-Loza; Nicolas Nesseler; Pascale Gaussem; Isabelle Gouin-Thibault
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

9.  P2Y2 and P2X4 Receptors Mediate Ca2+ Mobilization in DH82 Canine Macrophage Cells.

Authors:  Reece Andrew Sophocleous; Nicole Ashleigh Miles; Lezanne Ooi; Ronald Sluyter
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 10.  Control of Macrophage Inflammation by P2Y Purinergic Receptors.

Authors:  Dominik Klaver; Martin Thurnher
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.